Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer

Multikinase inhibitors (MKIs) targeting VEGF receptors and other receptor tyrosine kinases have shown considerable activity in clinical trials of thyroid cancer. Thyroid cancer frequently exhibits activation of the RAS/RAF/MEK/ERK pathway. In other types of cancer, paradoxical ERK activation has eme...

Descripción completa

Detalles Bibliográficos
Autores principales: BALL, DOUGLAS W., JIN, NING, XUE, PING, BHAN, SHEETAL, AHMED, SHABINA R., ROSEN, D. MARC, SCHAYOWITZ, ADAM, CLARK, DOUGLAS P., NELKIN, BARRY D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583528/
https://www.ncbi.nlm.nih.gov/pubmed/26324075
http://dx.doi.org/10.3892/or.2015.4225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583528/
https://www.ncbi.nlm.nih.gov/pubmed/26324075
http://dx.doi.org/10.3892/or.2015.4225

Ejemplares similares